Literature DB >> 26566807

MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Ai-Ming Yu1, Ye Tian2, Mei-Juan Tu2, Pui Yan Ho2, Joseph L Jilek2.   

Abstract

Knowledge of drug absorption, distribution, metabolism, and excretion (ADME) or pharmacokinetics properties is essential for drug development and safe use of medicine. Varied or altered ADME may lead to a loss of efficacy or adverse drug effects. Understanding the causes of variations in drug disposition and response has proven critical for the practice of personalized or precision medicine. The rise of noncoding microRNA (miRNA) pharmacoepigenetics and pharmacoepigenomics has come with accumulating evidence supporting the role of miRNAs in the modulation of ADME gene expression and then drug disposition and response. In this article, we review the advances in miRNA pharmacoepigenetics including the mechanistic actions of miRNAs in the modulation of Phase I and II drug-metabolizing enzymes, efflux and uptake transporters, and xenobiotic receptors or transcription factors after briefly introducing the characteristics of miRNA-mediated posttranscriptional gene regulation. Consequently, miRNAs may have significant influence on drug disposition and response. Therefore, research on miRNA pharmacoepigenetics shall not only improve mechanistic understanding of variations in pharmacotherapy but also provide novel insights into developing more effective therapeutic strategies.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Mesh:

Substances:

Year:  2015        PMID: 26566807      PMCID: PMC4767381          DOI: 10.1124/dmd.115.067470

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  163 in total

1.  MicroRNA-92b regulates expression of the oligopeptide transporter PepT1 in intestinal epithelial cells.

Authors:  Guillaume Dalmasso; Hang Thi Thu Nguyen; Yutao Yan; Hamed Laroui; Moiz A Charania; Tracy S Obertone; Shanthi V Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-10-28       Impact factor: 4.052

Review 2.  Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Authors:  E T Morgan
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

3.  The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma.

Authors:  Liu Hong; Yu Han; Hongwei Zhang; Mengbin Li; Taiqian Gong; Li Sun; Kaichun Wu; Qingchuan Zhao; Daiming Fan
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

4.  MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells.

Authors:  Jin Lu Tong; Chen Peng Zhang; Fang Nie; Xi Tao Xu; Ming Ming Zhu; Shu Dong Xiao; Zhi Hua Ran
Journal:  FEBS Lett       Date:  2011-10-22       Impact factor: 4.124

5.  Fumonisin B₁ modulates expression of human cytochrome P450 1b1 in human hepatoma (Hepg2) cells by repressing Mir-27b.

Authors:  Anil A Chuturgoon; Alisa Phulukdaree; Devapregasan Moodley
Journal:  Toxicol Lett       Date:  2014-03-12       Impact factor: 4.372

6.  miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1).

Authors:  Timothy J Pullen; Gabriela da Silva Xavier; Gavin Kelsey; Guy A Rutter
Journal:  Mol Cell Biol       Date:  2011-06-06       Impact factor: 4.272

Review 7.  Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants.

Authors:  Jr-Shiuan Yang; Eric C Lai
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

8.  The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4.

Authors:  Rommel G Tirona; Wooin Lee; Brenda F Leake; Lu-Bin Lan; Cynthia Brimer Cline; Vishal Lamba; Fereshteh Parviz; Stephen A Duncan; Yusuke Inoue; Frank J Gonzalez; Erin G Schuetz; Richard B Kim
Journal:  Nat Med       Date:  2003-01-06       Impact factor: 53.440

9.  MicroRNA regulates human vitamin D receptor.

Authors:  Takuya Mohri; Miki Nakajima; Shingo Takagi; Sayaka Komagata; Tsuyoshi Yokoi
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

10.  Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.

Authors:  Melanie A Felmlee; Hoi-Kei Lon; Frank J Gonzalez; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2007-11-29       Impact factor: 3.922

View more
  29 in total

Review 1.  Bioengineered non-coding RNA agent (BERA) in action.

Authors:  Zhijian Duan; Ai-Ming Yu
Journal:  Bioengineered       Date:  2016-07-14       Impact factor: 3.269

2.  Transcriptome association analysis identifies miR-375 as a major determinant of variable acetaminophen glucuronidation by human liver.

Authors:  Ioannis Papageorgiou; Marina Freytsis; Michael H Court
Journal:  Biochem Pharmacol       Date:  2016-08-13       Impact factor: 5.858

Review 3.  Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics.

Authors:  Baitang Ning; Dianke Yu; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2019-09-10       Impact factor: 5.858

Review 4.  RNA therapy: Are we using the right molecules?

Authors:  Ai-Ming Yu; Chao Jian; Allan H Yu; Mei-Juan Tu
Journal:  Pharmacol Ther       Date:  2018-12-04       Impact factor: 12.310

5.  Effects of MicroRNA-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice.

Authors:  Joseph L Jilek; Ye Tian; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2017-03-02       Impact factor: 3.922

6.  Identification and validation of microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily enzymes by a functional genomics approach.

Authors:  Ioannis Papageorgiou; Michael H Court
Journal:  Biochem Pharmacol       Date:  2017-04-19       Impact factor: 5.858

Review 7.  Bioengineering of noncoding RNAs for research agents and therapeutics.

Authors:  Pui Yan Ho; Ai-Ming Yu
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-01-13       Impact factor: 9.957

8.  Identification and validation of the microRNA response elements in the 3'-untranslated region of the UDP glucuronosyltransferase (UGT) 2B7 and 2B15 genes by a functional genomics approach.

Authors:  Ioannis Papageorgiou; Michael H Court
Journal:  Biochem Pharmacol       Date:  2017-09-28       Impact factor: 5.858

9.  Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.

Authors:  Mei-Juan Tu; Pui Yan Ho; Qian-Yu Zhang; Chao Jian; Jing-Xin Qiu; Edward J Kim; Richard J Bold; Frank J Gonzalez; Huichang Bi; Ai-Ming Yu
Journal:  Cancer Lett       Date:  2018-10-30       Impact factor: 8.679

Review 10.  Role of miRNAs in hypoxia-related disorders.

Authors:  A Gupta; R Sugadev; Y K Sharma; Y Yahmad; P Khurana
Journal:  J Biosci       Date:  2018-09       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.